Heterogeneity of obesity phenotypes in relation to cardiovascular risk
https://doi.org/10.15829/1728-8800-2019-1-161-167
Abstract
Obesity is associated with numerous metabolic disorders, the development and progression of a wide range of conditions and diseases, primarily cardiovascular disease and type 2 diabetes. One of the widely discussed phenomena of the association of obesity with cardiovascular diseases, their complications and mortality is the phenomenon of “heterogeneity of obesity phenotypes in relation to cardiovascular risk”. Currently, two main phenotypes have been identified — metabolically healthy and metabolically unhealthy obesity. At the same time, not only the expediency of separation, but also the existence of this phenotype is widely discussed today. The article provides an overview of existing approaches to the verification of metabolic phenotypes of obesity and data relating to the epidemiology and the association of metabolically healthy obesity with the risk of cardiovascular diseases and death, and also discusses the factors that determine the features of the obesity phenotype.
About the Authors
М. A. Druzhilov
Industrial hospital of the Federal Security Service Administration of Russia in the Republic of Karelia
Russian Federation
Petrozavodsk
Russian Federation
Petrozavodsk
Т. Yu. Kuznetsova
Petrozavodsk State University
Petrozavodsk
Petrozavodsk
References
1. World Health Organization. Obesity and overweight fact sheet. World Health Organization website. http://www.who.int/mediacentre/factsheets/fs311/en (15 July 2016).
2. The GBD 2015 Obesity Collaborators. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377:13-27. doi:10.1056/NEJMoa1614362.
3. Shlyakhto EV, Nedogoda SV, Konradi AO, et al. The concept of novel national clinical guidelines on obesity. Russ J Cardiol. 2016;4:7-13. (In Russ.) doi:10.15829/1560-4071-2016-4-7-13
4. Ortega F, Lavie C, Blair S. Obesity and Cardiovascular Disease. Circ Res. 2016;118:1752-70. doi:10.1161/CIRCRESAHA.115.306883.
5. Phillips C. Metabolically healthy obesity: definitions, determinants and clinical implications. Rev Endocr Metab Disord. 2013;14:219-27. doi:10.1007/s11154-013-9252-x.
6. Samocha-Bonet D, Dixit V, Kahn C, et al. Metabolically healthy and unhealthy obese: the 2013 Stock Conference report. Obes Rev. 2014;15(9):697-708. doi:10.1111/obr.12199.
7. Velho S, Paccaud F, Waeber G, et al. Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr. 2010;64(10):1043-51. doi:10.1038/ejcn.2010.114.
8. Hinnouho G, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. Eur Heart J. 2015;36(9):551-9. doi:10.1093/eurheartj/ehu123.
9. Eckel N, Meidtner K, Kalle-Uhlmann T, et al. Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(9):956-66. doi:10.1177/2047487315623884.
10. Garcia-Moll X. Obesity and prognosis: Time to forget about metabolically healthy obesity. Eur Heart J. 2018;39(5):407-9. doi:10.1093/eurheartj/ehx535.
11. Piepoli М, Hoes А, Agewall S, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2016). Eur Heart J. 2016;37(29):2315-81. doi: 10.1016/j.atherosclerosis.2016.05.037.
12. Romantsova TI, Ostrovskaya EV. Metabolically healthy obesity: definitions, protective factors, clinical relevance. Almanac of Clinical Medicine. 2015;1(1):75- 86. (In Russ.) doi:10.18786/2072-0505-2015-1-75-86.
13. Kim S, Després J, Koh K. Obesity and cardiovascular disease: friend or foe? Eur Heart J. 2016;37(48):3560-8. doi:10.1093/eurheartj/ehv509.
14. Park J, Kim S, Cho G, et al. Obesity phenotype and cardiovascular changes. J Hypertens. 2011;29(9):1765-72. doi:10.1097/HJH.0b013e32834a50f3.
15. Bobbioni-Harsch E, Pataky Z, Makoundou V, et al. From metabolic normality to cardiometabolic risk factors in subjects with obesity. Obesity (Silver Spring). 2012;20(10):2063-9. doi:10.1038/oby.2012.69.
16. Ortega F, Lee D, Katzmarzyk P, et al. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J. 2013;34(5):389- 97. doi:10.1093/eurheartj/ehs174.
17. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab. 2012;97(7):2482-8. doi:10.1210/jc.2011-3475.
18. Roberson L, Aneni E, Maziak W, et al. Beyond BMI: The “Metabolically healthy obese” phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality — a systematic review. BMC Public Health. 2014;14:14. doi:10.1186/1471-2458-14-14.
19. van Vliet-Ostaptchouk J, Nuotio M, Slagter S, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9. doi:10.1186/1472-6823-14-9.
20. Wildman R, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168(15):1617-24. doi:10.1001/archinte.168.15.1617.
21. Shea J, Randell E, Sun G. The Prevalence of Metabolically Healthy Obese Subjects Defined by BMI and Dual-Energy X-Ray Absorptiometry. Obesity. 2011;19(3):624-30. doi:10.1038/oby.2010.174.
22. Rey-López J, de Rezende L, Pastor-Valero M, et al. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. Obes Rev. 2014;15(10):781-90. doi:10.1111/obr.12198.
23. Hamer M, Bell J, Sabia S, et al. Stability of metabolically healthy obesity over 8 years: the English Longitudinal Study of Ageing. Eur J Endocrinol. 2015;173(5):703-8. doi:10.1530/EJE-15-0449.
24. Eshtiaghi R, Keihani S, Hosseinpanah F, et al. Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: the Tehran Lipid and Glucose Study. Int J Obes. 2015;39(3):514-9. doi:10.1038/ijo.2014.176.
25. Hwang Y, Hayashi T, Fujimoto W, et al. Visceral abdominal fat accumulation predicts the conversion of metabolically healthy obese subjects to an unhealthy phenotype. Int J Obes (Lond). 2015;39(9):1365-70. doi:10.1038/ijo.2015.75.
26. Calori G, Lattuada G, Piemonti L, et al. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care. 2011;34(1):210-5. doi:10.2337/dc10-0665.
27. Guo F, Garvey W. Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: stability of metabolic health status in adults. Obesity (Silver Spring). 2016;24(2):516-25. doi:10.1002/oby.21344.
28. Lassale C, Tzoulaki I, Moons K, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J. 2018;39(5):397-406. doi:10.1093/eurheartj/ehx448.
29. Caleyachetty R, Thomas G, Toulis K, et al. Metabolically healthy obese and incident cardiovascular desease events among 3,5 million men and women. JACC. 2017;70(12):1429-37. doi:10.1016/j.jacc.2017.07.763.
30. Hansen L, Netterstrøm M, Johansen N, et al. Metabolically healthy obesity and ischemic heart disease: A 10-year follow-up of the Inter99 Study. J Clin Endocrinol Metab. 2017;102(6):1934-42. doi:10.1210/jc.2016-3346.
31. Mongraw-Chaffin M, Foster M, Kalyani R, et al. Obesity severity and duration are associated with incident metabolic syndrome: evidence against metabolically healthy obesity from the Multi-Ethnic Study of Atherosclerosis. J Clin Endocrinol Metab. 2016;101(11):4117-24. doi:10.1210/jc.2016-2460.
32. Antonopoulos A, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovascular Research 2017;113:1074-86. doi:10.1093/cvr/cvx106.
33. Barry V, Baruth M, Beets M, et al. Fitness vs. fatness on all-cause mortality: a metaanalysis. Prog Cardiovasc Dis. 2014;56:382-90. doi:10.1016/j.pcad.2013.09.002.
34. Kramer C, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med. 2013;159(11):758-69. doi:10.7326/0003-4819-159-11-201312030-00008.
35. Fan J, Song Y, Chen Y, et al. Combined effect of obesity and cardiometabolic abnormality on the risk of cardiovascular disease: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;168(5):4761-8. doi:10.1016/j.ijcard.2013.07.230.
36. Blundell J, Dulloo A, Salvador J, et al. Beyond BMI — phenotyping the obesities. Obes Facts. 2014;7(5):322-8. doi:10.1159/000368783.
37. Franco L, Morais C, Cominetti C. Normal-weight obesity syndrome: diagnosis, prevalence, and clinical implications. Nutr Rev. 2016;74(9):558-70. doi:10.1093/nutrit/nuw019.
38. Titov VN, Dmitriev VA. Obesity is a pathology of adipocytes: cell number, arterial bed volume, local circulation pools in vivo, natriuretic peptides and arterial hypertension. Translational Medicine. 2015;1:26-38. (In Russ.) doi:10.18705/2311-4495-2015-0-1-26-38.
39. Alberti K, Eckel R, Grundy S, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; and International association for the study of obesity. Circulation. 2009;120(16):1640-5. doi:10.1161/CIRCULATIONAHA.109.192644.
40. Molica F, Morel S, Kwak B. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb Haemost. 2015;113(3):553-66. doi:10.1160/TH14-06-0513.
41. Nilsson P, Boutouyrie P, Laurent S. Vascular Aging: A Tale of EVA and ADAM in Cardiovascular Risk Assessment and Prevention. Hypertension. 2009;54(1):3-10. doi:10.1161/HYPERTENSIONAHA.109.129114.
42. Druzhilov MA, Druzhilova OYu, Kuznetsova TYu, et al. Obesity as cardiovascular risk factor: accent on quality and functional activity of adipose tissue. Russ J Cardiol. 2015;4:111-7. (In Russ.) doi:10.15829/1560-4071-2015-4-111-117.
43. Chumakova GA, Veselovskaya NG. Clinical significance of visceral obesity. Moscow: GEOTAR-Media, 2016. p. 200. (In Russ.) ISBN 978-5-9704-3988-3.
44. Appleton S, Seaborn C, Visvanathan R, et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care. 2013;36(8):2388-94. doi:10.2337/dc12-1971.
45. Kuznetsova TY, Chumakova GA, Druzhilov MA, et al. Clinical application of quantitative echocardiographic assessment of epicardial fat tissue in obesity. Russ J Cardiol. 2017;4:81-7. (In Russ.) doi:10.15829/1560-4071-2017-4-81-87.
46. Khan U, Ogorodnikova A, Xu L, et al. The adipokine profile of metabolically benign obese and at-risk normal weight postmenopausal women: the Women’s Health Initiative Observational Study. Obesity (Silver Spring). 2014;22(3):786-94. doi:10.1002/oby.20139.
47. Badoud F, Perreault M, Zulyniak M, et al. Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals. FASEB J. 2015;29(3):748-58. doi:10.1096/fj.14-263913.
48. Khan T, Muise E, Iyengar P, et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol. 2009;29(6):1575-91. doi:10.1128/MCB.01300-08.
49. Cedikova M, Kripnerovа M, Dvorakova J, et al. Mitochondria in white, brown, and beige adipocytes. Stem Cells Int, 2016; ID 6067349. doi:10.1155/2016/6067349
Review
For citations:
Druzhilov М.A., Kuznetsova Т.Yu. Heterogeneity of obesity phenotypes in relation to cardiovascular risk. Cardiovascular Therapy and Prevention. 2019;18(1):161-167. (In Russ.) https://doi.org/10.15829/1728-8800-2019-1-161-167
Views:
1049
Email this article 
